Truist lowered the firm’s price target on AdaptHealth (AHCO) to $13 from $14 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO:
- AdaptHealth’s Strategic Divestitures and Strong Financial Performance Justify Buy Rating
- AdaptHealth’s Growth Potential and Resilience Justify Buy Rating Amid Promising Segment Performances and Minimal Tariff Impact
- AdaptHealth Reports Q1 2025 Financial Results
- AdaptHealth’s Mixed Earnings Call Highlights Progress and Challenges
- AdaptHealth reports Q1 EPS (5c), consensus 4c